Title: Cyclophosphamide for clinical renal and hepatic transplantation.
Abstract: Cyclophosphamide was given as the initial cytotoxic drug in combination with prednisone and ALG to 61 renal recipients. After 1 mo or longer, azathioprine was substituted for cyclophosphamide for maintenance therapy. After 9–18 mo, the patient and kidney survivals with consanguineous transplantation are 91% and 81%, respectively, and after cadaveric renal transplantation the figures are 76% and 67%, respectively. These results are similar to those obtained in the past with azathioprine alone.
Sixteen recipients of orthotopic cadaveric livers were similarly treated with seven (44%) living after 2–18 mo. With avoidance of technical accidents and increased experience with cyclophosphamide, the record since January 1972 is five survivors of six. In these patients, little difficulty was encountered with control of rejection. This observation, plus recent evidence that azathioprine may not be immunosuppressive in patients with significant hepatic dysfunction, suggests that cyclophosphamide is the preferable primary cytotoxic drug for the early treatment of liver recipients.
Publication Year: 1973
Publication Date: 1973-03-01
Language: en
Type: article
Indexed In: ['pubmed']
Access and Citation
Cited By Count: 23
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot